Pasar al contenido principal

MODULACION DE LA RESPUESTA NATURAL KILLER EN EL RECONOCIMIENTO Y EVASION TUMORAL

RTI2018-093569-B-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos I+D+i Retos de Investigación
Año convocatoria 2018
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 12
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

BCG Therapy of bladder cancer stimulates a prolonged release of the chemoattractant CXCL10 (IP10) in patient urine

  • Ashiru, Omodele
  • Esteso, Gloria
  • García-Cuesta, Eva María
  • Castellano, Eva
  • Samba, Celia
  • Escudero-López, Eva
  • López-Cobo, Sheila
  • Álvarez-Maestro, Mario
  • Linares, Ana
  • Ho, Mei M.
  • Leibar, Asier
  • Martínez‐Piñeiro, Luis
  • Valés-Gómez, Mar
© 2019 by the authors., [Background]: Intra-vesical instillation of Bacille Calmette–Guérin (BCG), an attenuated strain of Mycobacterium bovis, is an effective therapy for high-grade non-muscle invasive bladder cancer (NMIBC), which provokes a local immune response resulting in 70% of patients free of relapse after three years. Because non-responder patients usually have a bad prognosis, the early identification of treatment failure is crucial. We hypothesized that, if an effective immune response was taking place in the bladder, soluble factors would be released to the urine many days after BCG instillations., [Methods]: An extensive panel of cytokines and chemokines released into the urine seven days after every BCG instillation was screened in a cohort of NMIBC patients over three years., [Results]: The determinations of the urinary concentrations of cytokines, chemokines, and creatinine showed that increasing concentrations of C-X-C motif chemokine 10 (CXCL10) also known as interferon-inducible protein 10 (IP10) could be detected during the six-week induction cycle of BCG-treated patients released into the urine by CD14+ cells. In vitro, CXCL10 facilitated the recruitment of effector immune cells after the BCG-mediated upregulation of CXCR3 in both T- and natural killer (NK)-cells. Conclusions: The high concentrations of chemokine detected one week after the encounter with mycobacteria suggest that the CXCL10 axis might be related to the intensity of the immune anti-tumor response., This research was funded by the Madrid Regional Government (S2010/BMD-2326 IMMUNOTHERCAN-CM (B2017/BMD-3733)/FEDER), and the Spanish Ministries of Economy and Health (SAF2015-69169-R, RTC-2017-6379-1, RTI2018-093569-B-I00 (MINECO/FEDER)); E.M.G.C. and S.L.C. were the recipients of fellowships from the La Caixa and Spanish Ministry of Education (FPU), respectively; C.S. was an Erasmus-visiting student from Sorbonne University. The APC was partially funded by CSIC., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

SARS-Cov-2 cysteine-like protease (Mpro) is immunogenic and can be detected in serum and saliva of COVID-19-seropositive individuals, SARS-CoV-2 protease antibodies in serum and saliva

  • Martinez-Fleta, Pedro
  • Alfranca, Arántzazu
  • González-Álvaro, Isidoro
  • Casasnovas, José María
  • Fernández-Soto, Daniel
  • Esteso, Gloria
  • Cáceres-Martell, Yaiza
  • Gardeta, Sofía
  • Prat, Salomé
  • Mateu-Alberoa, Tamara
  • Gabrie, Ligia
  • López-Granados, Eduardo
  • Sánchez-Madrid, Francisco
  • Rodríguez-Frade, José Miguel
  • Reyburn, H. T.
  • Valés-Gómez, Mar
Currently, there is a need for reliable tests that allow identification of individuals that have been infected with SARS-CoV-2 even if the infection was asymptomatic. To date, the vast majority of the serological tests for SARS-CoV-2 specific antibodies are based on serum detection of antibodies to either the viral spike glycoprotein (the major target for neutralising antibodies) or the viral nucleocapsid protein that are known to be highly immunogenic in other coronaviruses. Conceivably, exposure of antigens released from infected cells could stimulate antibody responses that might correlate with tissue damage and, hence, they may have some value as a prognostic indicator. We addressed whether other non-structural viral proteins, not incorporated into the infectious viral particle, specifically the viral cysteine-like protease, might also be potent immunogens. Using ELISA tests, coating several SARS-CoV-2 proteins produced in vitro, we describe that COVID-19 patients make high titre IgG, IgM and IgA antibody responses to the Cys-like protease from SARS-CoV-2, also known as 3CLpro or Mpro, and it can be used to identify individuals with positive serology against the coronavirus. Higher antibody titres in these assays associated with more severe disease and no cross-reactive antibodies against prior betacoronavirus were found. Remarkably, IgG antibodies specific for Mpro and other SARS-CoV-2 antigens can also be detected in saliva. In conclusion, Mpro is a potent antigen in infected patients that can be used in serological tests and its detection in saliva could be the basis for a rapid, non-invasive test for COVID-19 seropositivity., This work was supported by the Spanish National Research Council (CSIC, project number 202020E079) and grants from Madrid Regional Government IMMUNOTHERCAN [S2017/BMD-3733-2 (MVG)]; the Spanish Ministry of Science and Innovation [(MCIU/AEI/FEDER, EU): RTI2018-093569-B-I00 (MVG), SAF2017-82940-R (JMRF), SAF2017-83265-R (HTR); SAF2017-82886-R (FSM)]; RETICS Program of ISCIII [RD16/0012/0006; RIER (JMRF); RD16/0011/0012, PI18/0371 (IGA), PI19/00549 (AA)]. The study was also funded by La Caixa Banking Foundation (HR17-00016 to FSM) and Fondo Supera COVID (CRUE-Banco de Santander) to FSM, No
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

SARS-CoV-2 Cysteine-like Protease Antibodies Can Be Detected in Serum and Saliva of COVID-19–Seropositive Individuals

  • Martinez-Fleta, Pedro
  • Alfranca, Arántzazu
  • González-Álvaro, Isidoro
  • Casasnovas, José María
  • Fernández-Soto, Daniel
  • Esteso, Gloria
  • Cáceres-Martell, Yaiza
  • Gardeta, Sofía
  • López-Sanz, Celia
  • Prat, Salomé
  • Mateu-Alberoa, Tamara
  • Gabrie, Ligia
  • López-Granados, Eduardo
  • Sánchez-Madrid, Francisco
  • Reyburn, H. T.
  • Rodríguez-Frade, José Miguel
  • Valés-Gómez, Mar
Currently, there is a need for reliable tests that allow identification of individuals that have been infected with SARS-CoV-2 even if the infection was asymptomatic. To date, the vast majority of the serological tests for SARS-CoV-2–specific Abs are based on serum detection of Abs to either the viral spike glycoprotein (the major target for neutralizing Abs) or the viral nucleocapsid protein that is known to be highly immunogenic in other coronaviruses. Conceivably, exposure of Ags released from infected cells could stimulate Ab responses that might correlate with tissue damage and, hence, they may have some value as a prognostic indicator. We addressed whether other nonstructural viral proteins, not incorporated into the infectious viral particle, specifically the viral cysteine-like protease, might also be potent immunogens. Using ELISA tests, coating several SARS-CoV-2 proteins produced in vitro, we describe that COVID-19 patients make high titer IgG, IgM, and IgA Ab responses to the Cys-like protease from SARS-CoV-2, also known as 3CLpro or Mpro, and it can be used to identify individuals with positive serology against the coronavirus. Higher Ab titers in these assays associated with more-severe disease, and no cross-reactive Abs against prior betacoronavirus were found. Remarkably, IgG Abs specific for Mpro and other SARS-CoV-2 Ags can also be detected in saliva. In conclusion, Mpro is a potent Ag in infected patients that can be used in serological tests, and its detection in saliva could be the basis for a rapid, noninvasive test for COVID-19 seropositivity., This work was supported by the Spanish National Research Council (Project 202020E079) and grants from the Madrid Regional Government (IMMUNOTHERCAN S2017/BMD-3733-2 [to M.V.-G.]), the Spanish Ministry of Science and Innovation (MCIU/AEI/FEDER, EU: RTI2018-093569-B-I00 [to M.V.-G.], SAF2017-82940-R [to J.M.R.F.], SAF2017-83265-R [to H.T.R.], and SAF2017-82886-R [to F.S.-M.]), and RETICS Program of Instituto de Salud Carlos III (RD16/0012/0006; RIER [to J.M.R.F.], RD16/0011/0012 and PI18/0371 [to I.G.-A.], and PI19/00549 [to A.A.]). The study was also funded by La Caixa Banking Foundation (HR17-00016 to F.S.-M.) and Banco Santander Supera COVID to F.S.-M. This work has been cofunded by grant Covid 2019 from the Madrid Regional Government to Health Institute “La Princesa.”, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Identification of the first cases of complete CD16A deficiency: Association with persistent EBV infection

  • Pérez-Portilla, A.
  • Moraru, M.
  • Blázquez Moreno, Alfonso
  • Kolb, Philipp
  • García-Morato, María Bravo
  • Ranganath, Thanmayi
  • Esteso, Gloria
  • Gianelli, Carla
  • Rodríguez-Pena, Rebeca
  • Lozano-Rodríguez, Roberto
  • Torres-Canizales, Juan Manuel
  • Blish, Catherine A.
  • Valés-Gómez, Mar
  • Hengel, Hartmut
  • Vilches, Carlos
  • López-Granados, Eduardo
  • Reyburn, H. T.
During the clinical workup of an adolescent male with chronic active EBV disease, it was noted that natural killer (NK) cells of this individual did not express the Fc-receptor CD16A (Fig 1, A). The index patient, born to nonconsanguineous parents, was first seen when he was 11 years old, and an extended workup revealed persistently high levels of EBV-encoded small RNA (EBER) DNA in peripheral blood and multiple-organ infiltration with EBV-positive T lymphocytes including an IgA- and EBV-positive interstitial nephritis that eventually led to renal failure (see Case Report and Table E1 in this article’s Online Repository at www.jacionline.org)., This work was supported by grants SAF2014-58752-R and SAF2017-83265-R to H.T.R. and grant SAF2016-80363-C2-2-R to C.V. (Spanish Science agency/European Regional Development Fund, European Union, AEI/FEDER, EU). The group of M.V.-G. has also received funding from the Spanish Ministry of Science and Innovation (grant nos. RTC-2017-6379-1 and RTI2018-093569-B-I00 [MCIU/AEI/FEDER, EU]) and the regional government of Madrid (grant no. S2017/BMD-3733-2). The group of M.V.-G. also belongs to the research network TENTACLES (RED2018-102411-T) funded by the Spanish Ministry of Science. A.P.P. and A.B.M. acknowledge PhD studentships funded by the National Secretary of Higher Education, Science, Technology and Innovation (SENESCYT, Ecuador) and Spanish Ministry of Economy and Competitivity (MINECO), respectively (SVP-2014-068263). M.M. was supported by grant GCB15152947MELE from Fundación de la Asociación Española contra el Cáncer. Work in the laboratory of H.H. is supported by Infect-ERA grant TANKACY, BMBF 031L0090, and German Research Foundation (DFG) grant HE2526/9-1. E.L.G. has grants from the Spanish Association Against Cancer (AECC) and Carlos III Health Institute (grant no. PI16/01605). C.A.B. acknowledges support from the National Institutes of Health (grant no. DP2AI11219301).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Otros (Other)

Bead-assisted SARS-CoV-2 multi-antigen serological test allows effective identification of patients

  • Cáceres-Martell, Yaiza
  • Fernández-Soto, Daniel
  • Campos-Silva, Carmen
  • García-Cuesta, Eva María
  • Casasnovas, José María
  • Navas-Herrera, David
  • Beneítez-Martínez, Alexandra
  • Martinez-Fleta, Pedro
  • Alfranca, Arántzazu
  • Sánchez-Madrid, Francisco
  • Escudero López, Gabriela
  • Vilches, Carlos
  • Jara-Acevedo, Ricardo
  • Reyburn, H. T.
  • Rodríguez-Frade, José Miguel
  • Valés-Gómez, Mar
Many new aspects of COVID-19 disease, including different clinical manifestations, have been identified during the pandemic. The wide array of symptoms and variation in disease severity after SARS-CoV-2 infection might be related to heterogeneity in the immune responses of different patients. Here we describe a new method for a simple multi-antigen serological test that generates a full picture of seroconversion in a single reaction. The assay is based on the detection by flow cytometry of multiple immunoglobulin classes (isotypes) specific for four SARS-CoV-2 antigens: the Spike glycoprotein (one of the highly immunogenic proteins), its RBD fragment (the major target for neutralising antibodies), the nucleocapsid protein and the main cysteine-like protease. Until now, most diagnostic serological tests measured antibodies to only one antigen and some patients seemed to not make any antibody response. Our data reveal that while most patients respond against all the viral antigens tested, others show a marked bias to make antibodies against either proteins exposed on the viral particle or those released after cellular infection. Combining all the four antigens and using machine learning techniques, it was possible to clearly discriminate between patients and healthy controls with 100% confidence. Further, combination of antigens and different immunoglobulin isotypes in this multi-antigen assay improved the classification of patients with mild and severe disease. Introduction of this method will facilitate massive screenings of patients to evaluate their immune response. It could also support vaccination campaigns both to select non-immune individuals and to distinguish infected patients from vaccine responders., This work was supported by the Spanish National Research Council (CSIC, project numbers 202020E079 and CSIC-COVID19-028) and grants from Madrid Regional Government “IMMUNOTHERCAN” [S2017/BMD-3733-2 (MVG)]; the Spanish Ministry of Science and Innovation [(MCIU/AEI/FEDER, EU): RTI2018-093569-B-I00 (MVG), SAF2017-82940-R (JMRF), SAF2017-83265-R (HTR); SAF2017-82886-R (FSM)]; Health Institute Carlos III (ISCIII) [RETICS Program RD16/0012/0006; RIER (JMRF); PI19/00549 (AA)]. The study was also funded by “La Caixa Banking Foundation” (HR17-00016 to FSM) and Fondo Supera COVID (CRUE-Banco de Santander) to FSM., No
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Single-reaction multi-antigen serological test for comprehensive evaluation of SARS-CoV-2 patients by flow cytometry

  • Cáceres-Martell, Yaiza
  • Fernández-Soto, Daniel
  • Campos-Silva, Carmen
  • García-Cuesta, Eva María
  • Casasnovas, José María
  • Navas-Herrera, David
  • Beneítez-Martínez, Alexandra
  • Martinez-Fleta, Pedro
  • Alfranca, Arántzazu
  • Sánchez-Madrid, Francisco
  • Escudero López, Gabriela
  • Vilches, Carlos
  • Jara-Acevedo, Ricardo
  • Reyburn, H. T.
  • Rodríguez-Frade, José Miguel
  • Valés-Gómez, Mar
Here, we describe a new, simple, highly multiplexed serological test that generates a more complete picture of seroconversion than single antigen-based assays. Flow cytometry is used to detect multiple Ig isotypes binding to four SARS-CoV-2 antigens: the Spike glycoprotein, its RBD fragment (the main target for neutralizing antibodies), the nucleocapsid protein, and the main cysteine-like protease in a single reaction. Until now, most diagnostic serological tests measured antibodies to only one antigen and in some laboratory-confirmed patients no SARS-CoV-2-specific antibodies could be detected. Our data reveal that while most patients respond against all the viral antigens tested, others show a marked bias to make antibodies against either proteins exposed on the viral particle or those released after cellular infection. With this assay, it was possible to discriminate between patients and healthy controls with 100% confidence. Analysing the response of multiple Ig isotypes to the four antigens in combination may also help to establish a correlation with the severity degree of disease. A more detailed description of the immune responses of different patients to SARS-CoV-2 virus might provide insight into the wide array of clinical presentations of COVID-19., This work was supported by: Spanish National Research Council (CSIC-202020E079, CSIC-COVID19-028); Madrid Regional Government “IMMUNOTHERCAN” [S2017/BMD-3733-2 (MVG)]; Spanish Ministry of Science and Innovation [(MCIU/AEI/FEDER, EU, RTI2018-093569-B-I00 (MVG), SAF2017-82940-R (JMRF), SAF2017-83265-R (HTR); SAF2017-82886-R (FSM)]; Health Institute Carlos III (ISCIII) [RETICS Program RD16/0012/0006; RIER (EMGC); PI19/00549 (AA)]; “La Caixa Bank Foundation” (HR17-00016), Fondo Supera COVID (CRUE-Banco de Santander), both to FSM., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Cross-reactive cellular, but not humoral, immunity is detected between OC43 and SARS-CoV-2 NPs in people not infected with SARS-CoV-2: Possible role of cTFH cells

  • García-Jiménez, Álvaro Fernando
  • Cáceres-Martell, Yaiza
  • Fernández-Soto, Daniel
  • Martinez-Fleta, Pedro
  • Casasnovas, José María
  • Sánchez-Madrid, Francisco
  • Rodríguez-Frade, José Miguel
  • Valés-Gómez, Mar
  • Reyburn, H. T.
Multiple questions about SARS-CoV-2 humoral and cellular immunity remain unanswered. One key question is whether preexisting memory T or B cells, specific for related coronaviruses in SARS-CoV-2-unexposed individuals, can recognize and suppress COVID-19, but this issue remains unclear. Here, we demonstrate that antibody responses to SARS-CoV-2 antigens are restricted to serum samples from COVID-19 convalescent individuals. In contrast, cross-reactive T cell proliferation and IFN-γ production responses were detected in PBMCs of around 30% of donor samples collected prepandemic, although we found that these prepandemic T cell responses only elicited weak cTFH activation upon stimulation with either HCoV-OC43 or SARS-CoV-2 NP protein. Overall, these observations confirm that T cell cross-reactive with SARS-CoV-2 antigens are present in unexposed people, but suggest that the T cell response to HCoV-OC43 could be deficient in some important aspects, like TFH expansion, that might compromise the generation of cross-reactive TFH cells and antibodies. Understanding these differences in cellular responses may be of critical importance to advance in our knowledge of immunity against SARS-CoV-2., This work was supported by the Spanish National Research Council (CSIC, project numbers 202020E079 and CSIC-COVID19-028)and grants from Madrid Regional Government “IMMUNOTHERCAN”[S2017/BMD-3733-2(M.V.G.)];the Spanish Ministry of Science and Innovation [(MCIU/AEI/FEDER,EU):RTI2018-093569-B-I00(M.V.G.),SAF2017-82940-R(J.M.R.F.),SAF2017-83265-R(H.T.R.);SAF2017-82886-R(F.S.M.)];RETICSProgramofISCIII[RD16/0012/0006;RIER(J. M. R. F.)]. A. F. G. J. is a recipient of a fellowship (FPU18/01698)from the Spanish Ministry of Science and Education.D.F.S.isarecip-ientofafellowship (PRE2018-083200)from the Spanish Ministry of Science and Innovation. Both are graduate students in the Molecular Biosciences doctoral program of the Autonomous University of Madrid, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

A simple immunoassay for extracellular vesicle liquid biopsy in microliters of non-processed plasma

  • Campos-Silva, Carmen
  • Cáceres-Martell, Yaiza
  • Sánchez-Herrero, Estela
  • Sandúa, Amaia
  • Beneítez-Martínez, Alexandra
  • González, Álvaro
  • Provencio, Mariano
  • Romero, Atocha
  • Jara-Acevedo, Ricardo
  • Yáñez-Mó, María
  • Valés-Gómez, Mar
[Background]: Extracellular vesicles (EVs), released by most cell types, provide an excellent source of biomarkers in biological fluids. However, in order to perform validation studies and screenings of patient samples, it is still necessary to develop general techniques permitting rapid handling of small amounts of biological samples from large numbers of donors., [Results]: Here we describe a method that, using just a few microliters of patient’s plasma, identifies tumour markers exposed on EVs. Studying physico-chemical properties of EVs in solution, we demonstrate that they behave as stable colloidal suspensions and therefore, in immunocapture assays, many of them are unable to interact with a stationary functionalised surface. Using flocculation methods, like those used to destabilize colloids, we demonstrate that cationic polymers increase EV ζ-potential, diameter, and sedimentation coefficient and thus, allow a more efficient capture on antibody-coated surfaces by both ELISA and bead-assisted flow cytometry. These findings led to optimization of a protocol in microtiter plates allowing effective immunocapture of EVs, directly in plasma without previous ultracentrifugation or other EV enrichment. The method, easily adaptable to any laboratory, has been validated using plasma from lung cancer patients in which the epithelial cell marker EpCAM has been detected on EVs., [Conclusions]: This optimized high throughput, easy to automate, technology allows screening of large numbers of patients to phenotype tumour markers in circulating EVs, breaking barriers for the validation of proposed EV biomarkers and the discovery of new ones., This work was supported by the Spanish Ministry of Science and Innovation (MCIU/AEI/FEDER, EU) under Grants RTI2018-093569-B-I00 and RED2018-102411-T (Translational Network for clinical application of EV, Tentacles); Madrid Regional Government under Grant “IMMUNOTHERCAN” (S2017/BMD-3733-2) and IND2019/BMD-17258., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

ALK-Fusion Transcripts Can Be Detected in Extracellular Vesicles (EVs) from Nonsmall Cell Lung Cancer Cell Lines and Patient Plasma: Toward EV-Based Noninvasive Testing

  • Sánchez-Herrero, Estela
  • Campos-Silva, Carmen
  • Cáceres-Martell, Yaiza
  • Robado de Lope, Lucía
  • Sanz-Moreno, Sandra
  • Serna-Blasco, Roberto
  • Rodríguez-Festa, Alejandro
  • Ares Trotta, Dunixe
  • Martín-Acosta, Paloma
  • Patiño, Cristina
  • Coronado, María José
  • Beneítez-Martínez, Alexandra
  • Jara, Ricardo
  • Lago-Baameiro, Nerea
  • Camino, Tamara
  • Cruz-Bermúdez, Alberto
  • Pardo, María
  • González-Rumayor, Víctor
  • Valés-Gómez, Mar
  • Provencio, Mariano
  • Romero, Atocha
[Background]: ALK rearrangements are present in 5% of nonsmall cell lung cancer (NSCLC) tumors and identify patients who can benefit from ALK inhibitors. ALK fusions testing using liquid biopsies, although challenging, can expand the therapeutic options for ALK-positive NSCLC patients considerably. RNA inside extracellular vesicles (EVs) is protected from RNases and other environmental factors, constituting a promising source for noninvasive fusion transcript detection., [Methods]: EVs from H3122 and H2228 cell lines, harboring EML4-ALK variant 1 (E13; A20) and variant 3 (E6a/b; A20), respectively, were successfully isolated by sequential centrifugation of cell culture supernatants. EVs were also isolated from plasma samples of 16 ALK-positive NSCLC patients collected before treatment initiation., [Results]: Purified EVs from cell cultures were characterized by transmission electron microscopy (TEM), nanoparticle tracking analysis (NTA), and flow cytometry. Western blot and confocal microscopy confirmed the expression of EV-specific markers as well as the expression of EML4-ALK-fusion proteins in EV fractions from H3122 and H2228 cell lines. In addition, RNA from EV fractions derived from cell culture was analyzed by digital PCR (dPCR) and ALK-fusion transcripts were clearly detected. Similarly, plasma-derived EVs were characterized by NTA, flow cytometry, and the ExoView platform, the last showing that EV-specific markers captured EV populations containing ALK-fusion protein. Finally, ALK fusions were identified in 50% (8/16) of plasma EV-enriched fractions by dPCR, confirming the presence of fusion transcripts in EV fractions., [Conclusions]: ALK-fusion transcripts can be detected in EV-enriched fractions. These results set the stage for the development of EV-based noninvasive ALK testing., This study has been funded by Instituto de Salud Carlos III through the project “PI17/01977” (co-funded by European Regional Development Fund/European Social Fund “A way to make Europe”/“Investing in your future”). The work presented in this paper also received funding from the European Union's Horizon 2020 research and innovation program under grant agreement No 875160. E. Sánchez-Herrero was funded by the Consejería de Ciencia, Universidades e Innovación of the Comunidad de Madrid (Doctorados Industriales of the Comunidad de Madrid IND2019/BMD-17258). R. Serna-Blasco was funded by the Consejería de Educación, Juventud y Deporte of the Comunidad de Madrid and by the Fondo Social Europeo (Programa Operativo de Empleo Juvenil, and Iniciativa de Empleo Juvenil, PEJD-2018-PRE/BMD-8640). M. Valés-Gómez was funded by Spanish Ministry of Science and Innovation (MCIU/AEI/FEDER, EU) grant RTI2018-093569-B-I00 and Madrid Regional Government under grant “IMMUNOTHERCAN” (S2017/BMD-3733-2). This work was supported by GEIVEX, Network of Excellence in the Research and Innovation on Exosomes REDIEX, SAF2015-71231-REDT, Network of Excellence in Translational NeTwork for the CLinical application of Extracellular VesicleS (TeNTaCLES) (RED2018-102411-T). M. Provencio, grants from BristolMyers Squibb, Roche, and AstraZeneca., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

SARS-CoV-2 membrane protein-specific antibodies from critically ill SARS-CoV-2–infected individuals interact with Fc receptor–expressing cells but do not neutralize the virus

  • Fernández-Soto, Daniel
  • Bueno, P.
  • Garaigorta, Urtzi
  • Gastaminza, Pablo
  • Bueno, José L.
  • Duarte, Rafael F.
  • Jara, Ricardo
  • Valés-Gómez, Mar
  • Reyburn, H. T.
The membrane (M) glycoprotein of SARS-CoV-2 is one of the key viral proteins regulating virion assembly and morphogenesis. Immunologically, the M protein is a major source of peptide antigens driving T cell responses, and most individuals who have been infected with SARS-CoV-2 make antibodies to the N-terminal, surface-exposed peptide of the M protein. We now report that although the M protein is abundant in the viral particle, antibodies to the surface-exposed N-terminal epitope of M do not appear to neutralize the virus. M protein–specific antibodies do, however, activate antibody-dependent cell-mediated cytotoxicity and cytokine secretion by primary human natural killer cells. Interestingly, while patients with severe or mild disease make comparable levels of M antigen–binding antibodies, M-specific antibodies from the serum of critically ill patients are significantly more potent activators of antibody-dependent cell-mediated cytotoxicity than antibodies found in individuals with mild or asymptomatic infection., This work was supported by the Spanish National Research Council (CSIC, project numbers 202020E079 and CSIC-COVID19-028) and grants from Comunidad de Madrid (IMMUNOTHERCAN, S2017/BMD-3733-2 [M.V.-G.]), the Spanish Ministry of Science and Innovation (MCIN)/Spanish Research Agency (AEI) (MCIN/AEI/FEDER, EU: RTI2018-093569-B-I00, PID 2021-123795OB-I00 [both to M.V.-G.] and PID2020-115506RB-I00 [H.T.R.]). This research work was also funded by the European Commission—NextGenerationEU (Regulation EU 2020/2094), through the CSIC's Global Health Platform (PTI Salud Global). The Centro Nacional de Biotecnología also receives financial support from the Spanish State Research Agency (AEI/10.13039/501100011033) through the Severo Ochoa Programme for Centres of Excellence in R&D (SEV-2013-0347, SEV-2017-0712). D.F.S. is a recipient of a fellowship (PRE2018-083200) from the Spanish Ministry of Science and Innovation., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

BCG-activation of leukocytes is sufficient for the generation of donor-independent innate anti-tumor NK and γδ T-cells that can be further expanded in vitro

  • Esteso, Gloria
  • Felgueres, María José
  • García-Jiménez, Álvaro Fernando
  • Reyburn-Valés, Christina
  • Benguría, Alberto
  • Vázquez, Enrique
  • Reyburn, H. T.
  • Aguiló, Nacho
  • Martín, Carlos
  • Puentes, Eugenia
  • Murillo, Ingrid
  • Rodríguez, Esteban
  • Valés-Gómez, Mar
R code related to the main scRNA-seq figures can be found at https://github.com/algarji/BCG_scRNA-seq. Raw data of the scRNA-seq analysis will be found at GEO (https://www.ncbi.nlm.nih.gov/geo/), Bacillus Calmette-Guérin (BCG), the nonpathogenic Mycobacterium bovis strain used as tuberculosis vaccine, has been successfully used as treatment for non-muscle invasive bladder cancer for decades, and suggested to potentiate cellular and humoral immune responses. However, the exact mechanism of action is not fully understood. We previously described that BCG mainly activated anti-tumor cytotoxic NK cells with upregulation of CD56 and a CD16+ phenotype. Now, we show that stimulation of human peripheral blood mononuclear cells with iBCG, a preparation based on BCG-Moreau, expands oligoclonal γδ T-cells, with a cytotoxic phenotype, together with anti-tumor CD56high CD16+ NK cells. We have used scRNA-seq, flow cytometry, and functional assays to characterize these BCG-activated γδ T-cells in detail. They had a high IFNγ secretion signature with expression of CD27+ and formed conjugates with bladder cancer cells. BCG-activated γδ T-cells proliferated strongly in response to minimal doses of cytokines and had anti-tumor functions, although not fully based on degranulation. BCG was sufficient to stimulate proliferation of γδ T-cells when cultured with other PBMC; however, BCG alone did not stimulate expansion of purified γδ T-cells. The characterization of these non-donor restricted lymphocyte populations, which can be expanded in vitro, could provide a new approach to prepare cell-based immunotherapy tools., This work was supported by the Spanish Ministry of Science and Innovation under Grants (RTC-2017-6379-1, RTI2018-093569-B-I00, PID2021-123795OB-I00 [Ministerio de Ciencia, Innovación y Universidades (MCIU)/Agencia Estatal de Investigación (AEI)/European Regional Development Fund (FEDER, EU)], SAF2017-83265-R (HTR); and the regional government of Madrid [COMUNIDAD DE MADRID S2017/BMD-3733-2 (MVG)]; MJF is a fellow of the INPhINIT Doctoral Programme from La Caixa Foundation (LCF/BQ/DI19/11730039). AFGJ is a recipient of a fellowship (FPU18/01698) from the Spanish Ministry of Science and Education., Peer reviewed
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Natural Killer Anti-Tumor Activity Can Be Achieved by In Vitro Incubation With Heat-Killed BCG

  • Esteso, Gloria
  • Aguiló, Nacho
  • Julián, Esther|||0000-0002-6558-3978
  • Ashiru, Omodele
  • Ho, Mei. M.
  • Martín, Carlos
  • Váles-Gómez, Mar|||0000-0001-7424-3206
Natural Killer cell receptors allow this heterogeneous immune population to efficiently fight both tumors and infection, so their use as immunotherapy agents is an active field of research. Cytokine activation, particularly by myeloid cell-derived IL15, can induce potent NK anti-tumor responses. While studying the mechanism of action of intravesical instillations of Bacille Calmette-Guérin (BCG) as therapy for patients with high risk non-muscle invasive bladder cancer, we showed that BCG can activate a cytotoxic CD56 bright NK cell population which efficiently recognized bladder cancer cells. This pioneer immunotherapy provides an invaluable model to understand the role of different immune populations in tumor elimination. However, during the propagation of BCG worldwide a large number of genetically diverse BCG substrains developed. Here, we investigated the capacity of different BCG substrains to promote NK cell activation and confirmed that they were able to activate lymphocytes. Tice, Connaught and Moreau were the substrains with a stronger NK activation effect as measured by CD56 upregulation. Surprisingly, dead mycobacteria also stimulated PBMC cultures and we further demonstrate here that subcellular fractions of BCG-Tice, in the absence of live mycobacteria, could also induce an NK cell response. Lipids from BCG-Tice, but not from Mycobacterium bovis, stimulated NK cell activation and degranulation, whereas the aqueous fraction of either bacteria did not activate lymphocytes. However, delipidated BCG-Tice bacteria were able to activate effector cells (CD3 + CD56 + and NK, CD3 - CD56 +). These data demonstrate that different components of mycobacteria can stimulate different immune subpopulations resulting in phenotypes suitable for cancer elimination.